共 51 条
Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease
被引:19
作者:
Fani Maleki, Adham
[1
,2
]
Cisbani, Giulia
[1
,2
]
Plante, Marie-Michele
[1
,2
]
Prefontaine, Paul
[1
,2
]
Laflamme, Nataly
[1
,2
]
Gosselin, Jean
[2
,3
]
Rivest, Serge
[1
,2
]
机构:
[1] Laval Univ, Fac Med, Neurosci Lab, CHU Quebec Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada
[2] Laval Univ, Fac Med, Dept Mol Med, CHU Quebec Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada
[3] Laval Univ, Fac Med, Lab Innate Immun, CHU Quebec Res Ctr, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada
关键词:
NOD2;
receptor;
Monocytes;
Microglia;
Macrophages;
Alzheimer's disease;
Immunotherapy;
Brain blood vessels;
Cerebral amyloid angiopathy;
Synapse;
PASSIVE-AVOIDANCE TASK;
AMYLOID-BETA PEPTIDE;
SYNAPSE LOSS;
IN-VIVO;
CLEARANCE;
BRAIN;
PROTEIN;
NOD2;
MICROGLIA;
LRP1;
D O I:
10.1186/s12974-020-01893-3
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C(high)into Ly6C(low)monocytes. Previously, we have shown that Ly6C(low)monocytes play crucial roles in the pathology of a mouse model of Alzheimer's disease (AD). However, medications with mild immunomodulatory effects that solely target specific monocyte subsets, without triggering microglial activation, are rare. Methods Three months old APP(swe)/PS1 transgenic male mice and age-matched C57BL/6 J mice were used for high frequency (2 times/week) over 6 months and low frequency (once a week) over 3 months of intraperitoneally MDP (10 mg/kg) administrations. Flow cytometry analysis of monocyte subsets in blood, and behavioral and postmortem analyses were performed. Results Memory tests showed mild to a strong improvement in memory function, increased expression levels of postsynaptic density protein 95 (PSD95), and low-density lipoprotein receptor-related protein 1 (LRP1), which are involved in synaptic plasticity and amyloid-beta (A beta) elimination, respectively. In addition, we found monocyte chemoattractant protein-1(MCP-1) levels significantly increased, whereas intercellular adhesion molecule-1(ICAM-1) significantly decreased, and microglial marker (Iba1) did not change in the treatment group compared to the control. In parallel, we discovered elevated cyclooxygenase-2 (COX2) expression levels in the treated group, which might be a positive factor for synaptic activity. Conclusions Our results demonstrate that MDP is beneficial in both the early phase and, to some extent, later phases of the pathology in the mouse model of AD. These data open the way for potential MDP-based medications for AD.
引用
收藏
页数:12
相关论文